Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Franklin Templeton

Franklin Biotechnology Discovery Fund Class C (FBTDX)

Ticker FBTDX · · Holdings as of Jul 31, 2026

Expense ratio
1.76%$176/yr per $10k
5-yr return
+5.4%annualized
1-yr return
+50.2%as of Dec 2025
Net assets
$1.2Ball share classes
Holdings
126

Bottom line

Is FBTDX a good fund? The bottom line

FBTDX is the Class C share class of Franklin Biotechnology Discovery Fund, an actively managed technology sector mutual fund from Franklin Templeton.

It charges 1.76% — about $176 a year on every $10,000 invested, more expensive than 91% of technology sector funds we track.

It returned +50.2% over one year, +5.4% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.2 billion in net assets and 126 holdings, its largest position is Jazz Pharmaceuticals plc (5.7%) and the top 10 make up 36.3% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.76%)
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What FBTDX invests in

Capital appreciation.

"Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Funds investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companys most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such…

From the fund's prospectus (filed Aug 25, 2026).

FBTDX performance

Average annual total returns
1 yr5 yr10 yr
FBTDX+50.2%+5.4%+6.2%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full FBTDX performance history →

What FBTDX costs

On a $10,000 investment, FBTDX's 1.76% expense ratio costs about $176 a year. The prospectus estimates $1,887 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full FBTDX fee table →

FBTDX top 10 holdings

#Holding% of fund
1Jazz Pharmaceuticals plc5.66%
2Amgen, Inc.4.39%
3Gilead Sciences, Inc.3.86%
4Regeneron Pharmaceuticals, Inc.3.77%
5Argenx SE3.62%
6Vertex Pharmaceuticals, Inc.3.54%
7Franklin Institutional U.S. Government Money Market Fund3.18%
8Revolution Medicines, Inc.3.01%
9Guardant Health, Inc.2.76%
10Ascendis Pharma A/S2.56%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 36.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to FBTDX

More funds like FBTDX →

FBTDX FAQ

What is the expense ratio of FBTDX?
FBTDX's expense ratio is 1.76%, which works out to about $176 a year for every $10,000 invested. The prospectus estimates total costs of $1,887 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is FBTDX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.76%); 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does FBTDX hold?
FBTDX's largest holdings are Jazz Pharmaceuticals plc (5.7%), Amgen, Inc. (4.4%), Gilead Sciences, Inc. (3.9%), Regeneron Pharmaceuticals, Inc. (3.8%), Argenx SE (3.6%). It holds 126 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is FBTDX's 5-year return?
FBTDX returned +5.4% a year over the five years ending Dec 31, 2025, and +6.2% a year over ten years. Past performance does not guarantee future results.
Does FBTDX have a sales load?
No. FBTDX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages FBTDX?
FBTDX is offered by Franklin Templeton through Franklin Strategic Series.